Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension (BENEFiT)
The goal of the trial was to evaluate the oral endothelin receptor antagonist bosentan in patients with chronic thromboembolic pulmonary hypertension (CTEPH).